The CCMO considers that the clauses relating to the early closure of the study and publication in these models are in line with the CCMO Directive on the Evaluation of Clinical Trial Agreements. The Triapartit agreement is intended in the event that the sponsor`s management of a commercial clinical trial is outsourced to a contract research organization. CRO mCIA is supported by the UK Health Services, the National Institute for Health Research, the Association of British Healthcare Industries, the NHS Confederation, the Medical Schools Council, the UK Clinical Research Collaboration, the NHS Research Forum and the Institute for Clinical Research. To prepare the clinical trial agreement, you can use models written by a collaboration of parties gathered within the Dutch Clinical Research Foundation (DCRF). Two models are available: one for industry-funded research and the other for research initiated by researchers. Participants participated in Top Clinical Training Hospitals (STZ), the Netherlands Federation of University Medical Centers (NFU), the Association of Innovative Medicines, the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI/AvL) and the Association of Contract Research Organizations in the Netherlands (ACRON). In reviewing the Clinical Trials Agreement, an accredited medical research ethics committee (MREC) and the CCMO will follow the CCMO Clinical Trial Agreement Evaluation Directive. The directive applies to research within the scope of the WMO and where there is a written agreement between the parties to fund, organize and conduct the research. There are several types of agreements and you should use the one that best suits your type of study and sponsorship agreements. For more information, visit the IRAS website. National site location agreements help speed up the process of awarding trials in the NHS supported by industry, as there is no longer a need for site-by-site controls and local legal agreements. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly.
The range of model location agreements is supported by guidelines that specify the objectives and modalities of the use of the agreement in the development of clinical research contracts supported by pharmaceutical, biopharmaceutical or medical companies. If you are applying for HRA authorization for your study, you may also find it useful to refer to the standard document and HRA evaluation criteria, as this includes reflections on the use of model agreements. You can find the document on our HRA special approval page. Contracts and agreements can be concluded at many levels; Both inside and outside, both legally and legally. Examples include: these model agreements apply to health services in England, Northern Ireland, Scotland and Wales; they replace the 2011 country versions. The accompanying guidelines provide more general information, an overview of changes from the 2011 versions, and additional information on how models should be used and under what circumstances. For HRA-authorized studies, HRA`s initial evaluation letter (and HRA authorization letter) specifies the corresponding agreement for each type of site in a study. The document may refer to the declaration of activity and the timing of events, to a model of agreement (for example. B mCTA) or another sponsor document. The revision of the clinical trial agreement is limited to two aspects, based on the CCMO Directive on the Evaluation of Clinical Trial Agreements: for all clinical trials and clinical investigations (including CTMS, product studies, etc.), an agreement signed between the promoter and the host organisation is expected before the start of the site research.